Abstract 149P
Background
RAS mutations have been reported to be associated with the worst overall survival in colon cancer. However, the effect of RAS mutation on recurrence-free survival and recurrence patterns remains unclear. This exploratory study aimed to evaluate the impact of RAS mutations, especially the rare mutations type in recurrence patterns in patients with stage I-IV CRC, and to identify the risk factors predicting recurrence-free survival in colon cancer.
Methods
Full RAS mutations were analyzed using Sanger and pyrosequencing for 270 patients. The MSI status was determined using immunohistochemical analysis. The correlation between Molecular alterations and recurrence patterns and recurrence-free survival was investigated. Statistical analysis was performed using the Kaplan–Meier method and the log-rank test.
Results
The mean patient's age was 55,4±14.7 with a moderate dominance of the male sex (n=146; 54.1%). The rate of recurrence after the first-line therapy was 31.5% (n=85). 13 (15,3%) patients had local recurrence, and 72 (84,7%) had distal recurrence. The most common distal recurrence site was the liver (n=34 ; 40,0%), followed by the lung (n=19 ; 22,4%). Of the 270 patients, 85 (31,5%) experienced recurrence, among whom 52,9% had mutant full RAS status, and 48,2% had KRAS mutations. Outside KRAS exon 2 mutations or rare mutations, were identified in 22 (8.1%) patients. The p.Q61L (Nras exon 3) mutation had the highest frequency in the rare mutation group (n=5 ; 22,7%), followed by the p.A146T (Kras exon 4) variant (n=4 ; 18,2%). RAS mutation status, KRAS mutations, and rare mutations were more common in patients with lung recurrence. Rare mutation status was correlated with worse recurrence-free survival (p=0,001). Multivariate logistic regression analysis revealed that differentiation, perineural invasion, full RAS mutant status, and KRAS codon 12 mutations were independent factors for recurrence-free survival in colon cancer.
Conclusions
In this cohort, recurrence patterns seemed to be associated with rare RAS mutations. KRAS codon 12 mutations were the worst predictor of recurrence-free survival at all stages in our population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract